ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
4.1.2022 15:04:00 EET | Business Wire | Press release
ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. The study will be done at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220104005104/en/
(Photo: Business Wire)
“This is the fourth IND approval for our investigational drug Nantheia™ product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications. This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer. “We are excited to be working with the UCLA team and look forward to this trial advancing.”
This trial is being led by principal investigators Edythe London, Ph.D., Distinguished Professor of Psychiatry and Biobehavioral Sciences as well as Molecular and Medicinal Pharmacology at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D ., Professor of Psychiatry and Biobehavioral Sciences at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA. Funding for this trial is from the National Institute on Drug Abuse (NIDA). (Clinical Trials.gov Identifier: NCT03787628 )
“The approval of the IND for this important clinical trial is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic,” said Dr. London.
“With the IND approved we are now moving quickly to get the trial under way,” said Dr. De La Garza.
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder. The company employs patented delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. Jerusalem, Israel) to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. The company has successfully launched these products in the US, Australia, and the UK, with expansion into additional markets such as the EU, China, Africa, and other countries in Asia. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its technology portfolio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005104/en/
Contact information
ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
iQmetrix and Stratus HR Partner to Give Wireless Retailers a Complete, Outsourced HR Department14.10.2026 18:15:00 EEST | Press release
Stratus HR, a full-service human resources outsourcing provider, today announced a partnership with iQmetrix, the Intelligent Commerce Operating System for telecom. As a Professional Employer Organization (PEO), Stratus HR becomes the complete, outsourced HR partner for wireless retailers on iQmetrix – payroll, benefits, compliance, and on-call HR experts – so retail teams stay focused on selling and serving customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014178512/en/ Fully integrated with iQmetrix, Stratus HR’s custom-built technology connects the employee lifecycle to the store: new hires, terminations, rehires, position moves, and security-role updates flow straight into the point of sale (POS), while hours flow from the retailer’s iQmetrix system into payroll – eliminating double entry and pay errors, so every paycheck is accurate and every new hire hits the floor faster. Frontline teams get enterprise-leve
New Study Brings Ketogenic Therapy for Bipolar Disorder Directly to Rural Alabama Homes14.10.2026 18:00:00 EEST | Press release
Baszucki Group today announced funding for a clinical study to examine the impact of ketogenic therapy on people living with bipolar disorder in rural Central Alabama. This study, led by researchers at the University of Alabama at Birmingham Heersink School of Medicine Montgomery Regional Campus, will partner with Heart of Alabama Food Bank (HAFB), sourcing Alabama-raised meats and produce to introduce metabolic psychiatry to a region characterized by a high prevalence of serious mental illness and severe shortages in psychiatric care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014955753/en/ A new study led by Will Rutland of UAB Montgomery and funded by Baszucki Group aims to improve access to psychiatric treatment in rural areas. By partnering with a local food bank, researchers will evaluate both the psychiatric and metabolic effects of ketogenic therapy alongside existing treatment modalities for people with bipol
Ant International Obtains Key Licenses from the Central Bank of the UAE to Support Digital Payments in the AI Era14.10.2026 17:32:00 EEST | Press release
Ant International, a leading global provider of digital payments and financial technology, has secured a Retail Payment Services and Card Schemes (Category II) (RPSCS) license and Stored Value Facilities (SVF) license from the Central Bank of the UAE (CBUAE), aligning with the UAE’s broader agenda for innovation and digital transformation in the financial sector. “The RPSCS and SVF licenses mark a crucial milestone in Ant International’s efforts to support the UAE’s fintech ecosystem, aligning with the nation’s ‘We are UAE 2031’ digitalisation and fintech strategy,” said Leiming Chen, Chief Sustainability Officer and Senior Vice President of Ant International. “In accordance with the applicable CBUAE regulatory framework, we look forward to launching AI-powered global payment and account solutions to make cross-border payments and financial management more accessible." Obtaining the RPSCS license is an important step towards Antom, a leading merchant payment and digitisation services p
International Optics and Photonics Community Invited to SPIE Photonics West 202714.10.2026 17:01:00 EEST | Press release
SPIE, the international society for optics and photonics, invites the global optics and photonics community to register for SPIE Photonics West 2027, happening 30 January–4 February at the Moscone Center in San Francisco, California. The dynamic week draws 24,000 researchers, engineers, students, and business leaders from around the globe, providing technical presentations, exhibitions, and networking opportunities that fuel collaboration and real-world innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013654749/en/ SPIE Photonics West will be held 30 January-4 February 2027 in San Francisco, California. The annual event brings together 24,000 people from the global optics and photonics community to foster collaboration and innovation. SPIE anticipates more than 4,500 presentations will be given across six technical application areas: AR | VR | MR, focuses on augmented, virtual, and mixed reality BiOS, highlights
Toluna Appoints Amy Fenton as Chief Executive Officer14.10.2026 16:30:00 EEST | Press release
Toluna, a global leader in consumer insights and market research technology, today announces the appointment of Amy Fenton as Chief Executive Officer, effective October 15, 2026. Ms. Fenton succeeds Frédéric Charles Petit, who founded Toluna and has led the company for 25 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014103169/en/ Amy Fenton appointed as new Chief Executive Officer, Toluna The appointment concludes the structured succession process announced on October 8, 2026, led by the Board in close consultation with Mr. Petit and supported by a leading executive search firm. Ms. Fenton brings more than 30 years of leadership experience in the insights and analytics industry. She joins Toluna from MarketCast, where she served as Chief Executive Officer and a member of the Board of Directors, after leading the company’s operations, insights, and analytics. Before MarketCast, she was Chief Client Officer, North
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom